Cyclic nucleotide phosphodiesterase inhibition by a benzoic acid derivative

  title={Cyclic nucleotide phosphodiesterase inhibition by a benzoic acid derivative},
  author={J. Killackey and B. Killackey and R. Philp},
  journal={Agents and Actions},
Acetylsalicylic acid (ASA) and three structurally related benzoic acid derivatives, 2-acetylbenzoic acid (ABA), 3-methylphthalide (3-MP), and 3-hydroperoxy-3-methylphthalide (3-HMP), were tested for inhibitory effects on three human blood platelet cyclic nucleotide phosphodiesterase (PDE) activities. 3-MP caused a dose-dependent inhibition of the high and low affinity cyclic AMP PDE activities and the cyclic GMP PDE activity. 3-HMP had some inhibitory effects but only on the low affinity cyclic… Expand
1 Citations
Dibenzothiepins, phthalans and phthalides from 4-heterosubstituted dibenzothiins
Abstract The lithiation of 4-heterosubstituted dibenzothiins 1 (phenoxathiin, phenothiazine and thianthrene) with lithium and a catalytic amount of 4,4′-di- tert -butylbiphenyl (DTBB, 7.5% molar) inExpand


Cartilage cyclic nucleotide phosphodiesterase: inhibition by anti-inflammatory agents.
Insight is provided into the mechanism of action of certain anti-inflammatory agents and into the relationships between prostaglandins and inflammatory reactions in chicken epiphyseal and articular cartilage. Expand
Antiinflammatory properties of a hydroperoxide compound, structurally related to acetylsalicylic acid
3-Hydroperoxy-3-methylphthalide, a structural analog of acetylsalicylic acid, was found to have some antiinflammatory properties which are distinct from those of ASA. Expand
Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
Results indicate that Y-590 is a selective inhibitor of cAMP-PDE which exerts its anti-platelet activity by inhibiting cAMP degradation in platelets. Expand
TVX 2706 — a new phosphodiesterase inhibitor with antiinflammatory action Biochemical characterization
The effects of the anti-inflammatory and analgesic drug 3-ethyl-1-(3-nitrophenyl)-2,4[1H, 3H]-quinazolindione (TVX 2706) on neuronal and glial cell culture systems including neuroblastoma × gliomaExpand
Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation.
It is suggested that MY-5445 inhibits human platelet aggregation by increasing cyclic GMP content and that it provides a useful probe for elucidating the role of cyclicGMP in platelets aggregation. Expand
Effects of sodium salicylate and acetylsalicylic acid on the lipolytic system of fat cells.
Inhibition of lipolysis stimulated by dibutyryl-cyclic 3',5'-AMP indicate that the observed reduction of binding between protein kinase and cyclic 3,5',AMP may be essential for the antilipolytic effect of both compounds. Expand
The effects of some benzoic acid derivatives on polymorphonuclear leukocyte accumulation in vivo.
It is indicated that drug effects on PMN leukocyte accumulation is an important determinant of anti-inflammatory potential. Expand
Comparison of the inhibitory effects of acetylsalicylic acid and trifusal on enzymes related to thrombosis.
Triflusal is a new antithrombotic agent, structurally similar to acetylsalicylic acid (ASA), which has been shown to possess a different pharmacological profile, suggesting a different mechanism ofExpand
Relationship of inhibition of prostaglandin synthesis in platelets to anti-aggregatory and anti-inflammatory activity of some benzoic acid derivatives
There is not a good correlation between ability to inhibit platelet PG synthesis, anti-aggregatory activity and anti-inflammatory activity, and multiple mechanisms of action, differing sensitivities of various tissue PG synthetases, or unidentified factors could be involved. Expand
Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: possible explanation of mechansim of inhibition of platelet function.
Close correspondence was taken to indicate that these drugs exert many of their effects on platelet function by altering the relative cAMP, cGMP levels and supports the contention that platelet aggregation and release are modulated both by cAMP and cG MP. Expand